146 related articles for article (PubMed ID: 27515221)
1. Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer - A new potential biomarker?
Golčić M; Petković M
Med Hypotheses; 2016 Sep; 94():148-50. PubMed ID: 27515221
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapy for Metastatic Renal Cell Carcinoma.
Afriansyah A; Hamid AR; Mochtar CA; Umbas R
Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
[TBL] [Abstract][Full Text] [Related]
3. Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?
Tassi R; Baldazzi V; Lapini A; Carini M; Mazzanti R
Clin Genitourin Cancer; 2015 Apr; 13(2):e101-5. PubMed ID: 25450040
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
5. A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma.
Jobard E; Blanc E; Négrier S; Escudier B; Gravis G; Chevreau C; Elena-Herrmann B; Trédan O
Br J Cancer; 2015 Oct; 113(8):1148-57. PubMed ID: 26372698
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of metastatic renal cell carcinoma].
Thuret R; Maurin C; Sun M; Perrotte P; Karakiewicz PI
Prog Urol; 2011 Apr; 21(4):233-44. PubMed ID: 21482396
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
8. An update on targeted therapy in metastatic renal cell carcinoma.
Lombardi G; Zustovich F; Donach M; Dalla Palma M; Nicoletto O; Pastorelli D
Urol Oncol; 2012; 30(3):240-6. PubMed ID: 20456985
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
Hess G; Borker R; Fonseca E
Clin Genitourin Cancer; 2013 Jun; 11(2):161-7. PubMed ID: 23267717
[TBL] [Abstract][Full Text] [Related]
10. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
[TBL] [Abstract][Full Text] [Related]
11. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.
Terakawa T; Miyake H; Kusuda Y; Fujisawa M
Urol Oncol; 2013 May; 31(4):493-8. PubMed ID: 21478036
[TBL] [Abstract][Full Text] [Related]
12. mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review.
Gerullis H; Ecke TH; Eimer C; Heuck CJ; Otto T
Minerva Urol Nefrol; 2010 Dec; 62(4):411-23. PubMed ID: 20944541
[TBL] [Abstract][Full Text] [Related]
13. Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers.
Castellano D; Ravaud A; Schmidinger M; De Velasco G; Vazquez F
Cancer Treat Rev; 2013 May; 39(3):230-40. PubMed ID: 22647546
[TBL] [Abstract][Full Text] [Related]
14. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Leung HW; Chan AL
Clin Ther; 2011 Jun; 33(6):708-16. PubMed ID: 21704235
[TBL] [Abstract][Full Text] [Related]
15. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
[TBL] [Abstract][Full Text] [Related]
16. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
Iacovelli R; Palazzo A; Trenta P; Mezi S; Pellegrino D; Naso G; Cortesi E
Am J Clin Oncol; 2014 Dec; 37(6):611-5. PubMed ID: 23388560
[TBL] [Abstract][Full Text] [Related]
17. [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
Siebels M; Staehler M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
Aktuelle Urol; 2010 Mar; 41(2):122-30. PubMed ID: 19937556
[TBL] [Abstract][Full Text] [Related]
18. Clinical management of metastatic kidney cancer: the role of new molecular drugs.
Vitale MG; Cartenì G
Future Oncol; 2016 Jan; 12(1):83-93. PubMed ID: 26617188
[TBL] [Abstract][Full Text] [Related]
19. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
[TBL] [Abstract][Full Text] [Related]
20. TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery.
Verzoni E; Ratta R; Grassi P; Salvioni R; Stagni S; Montone R; Fucà G; Cappelletti V; Reduzzi C; De Giorgi U; Procopio G
Tumori; 2018 Oct; 104(5):401-405. PubMed ID: 29192741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
